Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function
- PMID: 33149181
- PMCID: PMC7643137
- DOI: 10.1038/s41598-020-75886-w
Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function
Abstract
Airway inflammation and chronic lung infections in cystic fibrosis (CF) patients are mostly caused by bacteria, e.g. Pseudomonas aeruginosa (PA). The role of fungi in the CF lung is still not well elucidated, but evidence for a harmful and complex role is getting stronger. The most common filamentous fungus in CF is Aspergillus fumigatus (AF). Age and continuous antibiotic treatment have been discussed as risk factors for AF colonisation but did not differentiate between transient and persistent AF colonisation. Also, the impact of co-colonisation of PA and AF on lung function is still under investigation. Data from patients with CF registered in the German Cystic Fibrosis Registry database in 2016 and 2017 were retrospectively analysed, involving descriptive and multivariate analysis to assess risk factors for transient or persistent AF colonisation. Age represented an independent risk factor for persistent AF colonisation. Prevalence was low in children less than ten years, highest in the middle age and getting lower in higher age (≥ 50 years). Continuous antibiotic lung treatment was significantly associated with AF prevalence in all age groups. CF patients with chronic PA infection had a lower lung function (FEV1%predicted), which was not influenced by an additional AF colonisation. AF colonisation without chronic PA infection, however, was significantly associated with a lower function, too. Older age up to 49 years and continuous antibiotic use were found to be the main risk factors for AF permanent colonisation. AF might be associated with decrease of lung function if not disguised by chronic PA infection.
Conflict of interest statement
The authors declare no competing interests.
Figures



Similar articles
-
Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis.BMC Pulm Med. 2017 Apr 21;17(1):70. doi: 10.1186/s12890-017-0416-4. BMC Pulm Med. 2017. PMID: 28431569 Free PMC article.
-
Change in lung clearance index with microbiological status in children with cystic fibrosis.Pediatr Pulmonol. 2019 Jun;54(6):729-736. doi: 10.1002/ppul.24278. Epub 2019 Mar 5. Pediatr Pulmonol. 2019. PMID: 30838817
-
The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis - preliminary report.Dev Period Med. 2015 Jan-Mar;19(1):66-79. Dev Period Med. 2015. PMID: 26003072
-
The co-colonization prevalence of Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis: A systematic review and meta-analysis.Microb Pathog. 2018 Dec;125:122-128. doi: 10.1016/j.micpath.2018.09.010. Epub 2018 Sep 11. Microb Pathog. 2018. PMID: 30217514
-
Aspergillus infections in cystic fibrosis.J Infect. 2016 Jul 5;72 Suppl:S50-5. doi: 10.1016/j.jinf.2016.04.022. Epub 2016 May 11. J Infect. 2016. PMID: 27177733 Review.
Cited by
-
Respiratory Outcomes and Aspergillus Serology Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection.Lung. 2025 Jan 6;203(1):24. doi: 10.1007/s00408-024-00781-4. Lung. 2025. PMID: 39762638
-
Pathogenicity and virulence of Aspergillus fumigatus.Virulence. 2023 Dec;14(1):2172264. doi: 10.1080/21505594.2023.2172264. Virulence. 2023. PMID: 36752587 Free PMC article. Review.
-
Recent Advances in Fungal Infections: From Lung Ecology to Therapeutic Strategies With a Focus on Aspergillus spp.Front Med (Lausanne). 2022 Mar 21;9:832510. doi: 10.3389/fmed.2022.832510. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35386908 Free PMC article. Review.
-
Emerging Fungal Threats in Cystic Fibrosis.Mycopathologia. 2021 Oct;186(5):639-653. doi: 10.1007/s11046-021-00574-w. Epub 2021 Jul 28. Mycopathologia. 2021. PMID: 34319568 Review.
-
Coil embolisation for massive haemoptysis in cystic fibrosis.BMJ Open Respir Res. 2021 Aug;8(1):e000985. doi: 10.1136/bmjresp-2021-000985. BMJ Open Respir Res. 2021. PMID: 34385150 Free PMC article.
References
-
- German Cystic Fibrosis Registry, Annual Report 2018. https://www.muko.info/fileadmin/user_upload/angebote/qualitaetsmanagemen...
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical